Clinical trials: Leukemia Acute Myeloid
Acute Myelogenous Leukemia, High-Grade Myelodysplastic Syndrome
A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome
This is an open-label, multicenter, phase 2 study of alisertib (MLN8237) in participants with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
- Trial name
- NCT00830518
- Testing
- Alisertib
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Acute Myeloid Leukemia, Relapsed Adult AML
Venetoclax and Lintuzumab-Ac225 in AML Patients
The study is a multicenter, open label Phase I/II trial. 1. To determine the maximum tolerated dose (MTD) of lintuzumab-Ac225 added to venetoclax for patients with CD33 positive relapsed/refractory AML. (Phase 1 portion) 2.
- Trial name
- NCT03867682
- Testing
- Lintuzumab-Ac225, Venetoclax, Spironolactone
- Where
- 5 sites in United States
- Volunteers
- 38 people
- Sponsor
- Actinium Pharmaceuticals
Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC)
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
This is a first-in-human, multi-center, open-label clinical study with separate dose escalation (Phase 1) and expansion (Phase 2) stages to assess preliminary safety, tolerability, and efficacy of the second generation oral XPO1…
- Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS)
- Trial name
- NCT02649790
- Testing
- KPT-8602, ASTX727, Dexamethasone
- Where
- 46 sites in United States, Canada and 3 more
- Volunteers
- 277 people
- Sponsor
- Karyopharm Therapeutics Inc
Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
This protocol will allow ponatinib with refractory Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia
- Trial name
- NCT04233346
- Testing
- Ponatinib 30mg OD, Ponatinib 45mg OD
- Where
- 14 sites in China
- Volunteers
- 93 people
- Sponsor
- Otsuka Beijing Research Institute
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes
This study is being performed to assess the safety, tolerability, and preliminary clinical effects of BVD-523 given orally, twice daily for 21-day cycles, in patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic…
- Trial name
- NCT02296242
- Testing
- BVD-523
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- BioMed Valley Discoveries, Inc
Acute Promyelocytic Leukemia
Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia
The purpose of this study is to determine whether NRX 195183 is effective in the treatment of relapsed or refractory Acute Promyelocytic Leukemia
- Trial name
- NCT00675870
- Testing
- NRX 195183 Soft Gelatin Capsule
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- NuRx Pharmaceuticals, Inc.
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients
CWP232291 blocks proliferation of cancer cells via activation of caspases. Active caspase have been shown to target beta-catenin, the hallmark of canonical Wnt signaling, for degradation through caspase-directed cleavage.
- Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelofibrosis
- Trial name
- NCT01398462
- Testing
- CWP232291
- Where
- 5 sites in United States, South Korea
- Volunteers
- 69 people
- Sponsor
- JW Pharmaceutical
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML)
This is the first study of the drug CT53518 when given to humans. The purpose of this study is to determine the highest dose of CT53518 that can safely be given to patients with Acute Myelogenous Leukemia (AML) and to identify…
- Trial name
- NCT00064584
- Testing
- CT53518
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Acute Myeloid Leukemia, Lymphoma, Mantle-Cell
A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer
The goal of this clinical trial is To assess the safety and tolerability of PEP07 administered orally as a single dose and at escalating dose levels, and, to determine the dose-limiting toxicity (DLT) of study treatment in…
- Trial name
- NCT05659732
- Testing
- PEP07
- Where
- 5 sites in Australia, Taiwan
- Volunteers
- 32 people
- Sponsor
- PharmaEngine
Acute Myelogenous Leukemia
Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)
This Phase 1b study will determine the maximum tolerated dose of KX2-391 given as a once-daily dose, in elderly patients with acute myelogenous leukemia.
- Trial name
- NCT01397799
- Testing
- KX2-391
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Kinex Pharmaceuticals Inc.
Myelodysplastic Syndromes, Leukemia, Myeloid, Acute
A Study to Analyze the Occurrence of Transformation From Myelodysplastic Syndrome to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndrome Who Received Revlimid® 5 mg Capsules and Who Are Continuing or no Longer Continuing Revlimid Treatment
To analyze the occurrence of transformation from myelodysplastic syndrome (MDS) to acute myeloid leukemia (hereinafter referred to as transformation from MDS to AML) in patients with myelodysplastic syndrome with a deletion 5q…
- Trial name
- NCT02921815
- Where
- Japan
- Volunteers
- 84 people
- Sponsor
- Celgene
Acute Myeloid Leukemia, Relapsed, Adult
A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Phase I, open label, non-randomized, multicenter, prospective dose escalation study of F16IL2 in combination with very low-dose cytarabine in subjects with acute myeloid leukemia relapse after allogeneic hematopoietic stem cell…
- Trial name
- NCT02957032
- Testing
- F16IL2, cytarabine
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Philogen S.p.A.
Acute Myeloid Leukemia
First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
This study is a First In Human, phase 1, open-label, non-randomized, multi-center, multiple ascending dose escalation study evaluating AFM28 as a monotherapy in subjects with Relapsed/Refractory CD123-positive Acute Myeloid…
- Trial name
- NCT05817058
- Testing
- AFM28
- Where
- 5 sites in France, Spain
- Volunteers
- 30 people
- Sponsor
- Affimed GmbH
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
The purpose of this study is to provide decitabine to patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) who have completed participation per protocol in the DACO-018 study.
- Trial name
- NCT00760084
- Testing
- Decitabine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Eisai Inc.
AML, Adult
A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)
This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy and PK of APG-2575 in combination with Azacitidine in the patients with AML/MPAL or MDS/CMML.
- Trial name
- NCT04964518
- Testing
- APG 2575 ramp up arm
- Where
- 9 sites in United States, Australia
- Volunteers
- 24 people
- Sponsor
- Ascentage Pharma Group Inc.
AML, Acute Myeloid Leukemia
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
This is a two Part study in patients with relapsed/refractory acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), or high risk myelodysplastic syndrome (MDS) that will initially evaluate the safety and…
- Conditions
- AML, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, CMML
- Trial name
- NCT04358393
- Testing
- APG-115, 5-azacitidine
- Where
- 8 sites in United States
- Volunteers
- 69 people
- Sponsor
- Ascentage Pharma Group Inc.
AML (Acute Myelogenous Leukemia, Relapsed Acute Myelogenous Leukemia
Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of WBC100 capsules in patients with relapsed or refractory acute myeloid leukemia (R/R AML).
- Conditions
- AML (Acute Myelogenous Leukemia, Relapsed Acute Myelogenous Leukemia, Refractory Acute Myeloid Leukemia, Hematologic Malignancy
- Trial name
- NCT07014449
- Testing
- WBC100 QD
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Hangzhou Weben Pharma Co., Ltd
Acute Myelogenous Leukemia (AML)
Expanded Access for CC-486
This is an expanded access program (EAP) for eligible participants designed to provide access to CC-486.
- Trial name
- NCT03723135
- Testing
- CC-486
- Where
- United States
- Sponsor
- Celgene
Acute Myeloid Leukemia
Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia
The goal of this clinical study is to learn more about the safety and dosing of the study drug, KITE-222, in participants with relapsed/refractory (r/r) acute myeloid leukemia (AML).
- Trial name
- NCT04789408
- Testing
- Cyclophosphamide, Fludarabine, KITE-222
- Where
- 9 sites in United States, France
- Volunteers
- 15 people
- Sponsor
- Kite, A Gilead Company
Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Rollover Study of BMS-354825 in Patients With CML and Ph+ALL
To assess the safety of dasatinib (BMS-354825) in subjects with Imatinib resistant or intolerant chronic myelogenous leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) who are resistant…
- Trial name
- NCT01030718
- Testing
- dasatinib
- Volunteers
- 54 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.